EWTX
NASDAQEdgewise Therapeutics Inc.
News · 26 weeks49+30%
2025-12-282026-06-21
Mix3290d
- Other12(38%)
- Insider11(34%)
- SEC Filings9(28%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Brege Laura4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERSEC Form 4 filed by Director Thompson Peter A.4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERSEC Form 4 filed by Director Morris Arlene4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERSEC Form 4 filed by Director Edris Badreddin4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERSEC Form 4 filed by Director Martin Christopher Nathan4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERSEC Form 4 filed by Director Fox Jonathan C4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- PRBiotech Bulls Stampede as Clinical Wins and Milestones Fuel MomentumDENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Multiple clinical-stage companies are delivering meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell therapy expansion to neurodegenerative disease programs and cardiovascular breakthroughs, investors were presented with a wave of catalysts that are driving enthusiasm across several emerging healthcare names. Traders appeared particularly focused on companies advancing toward late-stage clinical development, securing new regulatory clearances, or gaining broader visibility through public market events. Download the 24/7 Market News App here https://app.247mnn.com/ or on the A
- PREdgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM –– EDG-7500 administration continued to be generally well tolerated –– Company to host webcast today at 8:30 a.m. Eastern Time –BOULDER, Colo., June 16, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line results from the 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 in obstructive (oHCM) and nonobstructive (nHCM) HCM. EDG-
- SECEdgewise Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- PREdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesBOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on May 29, 2026, Edgewise granted inducement stock options to purchase a total of 74,000 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). Each
- SECSEC Form 8-K filed by Edgewise Therapeutics Inc.8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- PREdgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline— Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones —— Transaction Creates Focused Cardiovascular Company with Enhanced Strategic Clarity —— Upfront Proceeds Expected to Fully Fund EDG-7500 Development Through Potential Approval —— On Track to Report 12-Week CIRRUS-HCM Part D Data in Q2 2026 —BOULDER, Colo., June 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will
- PRServier to Acquire Edgewise Therapeutics' Muscular Dystrophy BusinessAcquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. Transaction represents total value of up to $2.65 billion.SURESNES, France, June 1, 2026 /CNW/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on developing innovative therapies for serious muscle disorders, for up to $2.65 billion, including upfront pa
- SECSEC Form SCHEDULE 13G filed by Edgewise Therapeutics Inc.SCHEDULE 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)
- PREdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, at 10:00 am ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start t
- PRAchieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona PharmaSEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced three senior leadership appointments. Christopher Martin has joined the Company's Board of Directors. Mark Zappia has joined as Senior Vice President, Commercial, where he will spearhead the Company's commercial function. Jim Willis has joined as Vice President of Sales and Sales Enablement, where he will lead the field force. Mr. Martin most recently served as Chief Commercia
- SECSEC Form S-8 filed by Edgewise Therapeutics Inc.S-8 - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- SECEdgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- SECSEC Form 10-Q filed by Edgewise Therapeutics Inc.10-Q - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- PREdgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications– Announced positive long-term sevasemten data demonstrating sustained functional stabilization in Becker muscular dystrophy (Becker) up to 3.5 years of follow-up –– CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in Q2 2026 –– Pivotal GRAND CANYON results for sevasemten in Becker expected in Q4 2026 –BOULDER, Colo., May 7, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2026 and recent business highlights.
- SECSEC Form 144 filed by Edgewise Therapeutics Inc.144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)
- INSIDERCMO Donovan Joanne M. sold $2,092,063 worth of shares (55,230 units at $37.88) as part of a pre-agreed trading plan and exercised 50,000 shares at a strike of $7.08, decreasing direct ownership by 54% to 4,367 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- PREdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesBOULDER, Colo., May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on April 30, 2026, Edgewise granted inducement stock options to purchase a total of 266,000 shares of Edgewise's common stock to 9 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). Each i
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Edgewise Therapeutics Inc.SCHEDULE 13D/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)
- SECSEC Form DEFA14A filed by Edgewise Therapeutics Inc.DEFA14A - Edgewise Therapeutics, Inc. (0001710072) (Filer)
EWTX FAQ
7 questionsWhat does Edgewise Therapeutics Inc. do?
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.Where does EWTX stock trade?
Edgewise Therapeutics Inc. (EWTX) is listed on NASDAQ.What sector and industry is EWTX in?
Edgewise Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Edgewise Therapeutics Inc. go public?
Edgewise Therapeutics Inc. (EWTX) completed its IPO in 2021.What are analysts saying about EWTX?
Edgewise Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Neutral with a $2000.00 price target on 2025-09-25. Recent price targets range from $1400.00 to $4600.00.What companies are similar to EWTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare EWTX side-by-side with any of them on Quantisnow.How can I track EWTX on Quantisnow?
Quantisnow aggregates Edgewise Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EWTX to receive live email and push alerts on every new disclosure.